#151705

Anti-CLEC9A [1F6]

Cat. #151705

Anti-CLEC9A [1F6]

Cat. #: 151705

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Mouse DNGR1

Class: Monoclonal

Application: FACS ; IF ; WB

Reactivity: Mouse

Host: Rat

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Caetano Reis e Sousa

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-CLEC9A [1F6]
  • Alternate name: C-Type Lectin Domain Family 9 Member A; HEEE9341; UNQ9341; DNGR-1; CD37; DNGR1
  • Clone: 1F6
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Mouse
  • Host: Rat
  • Application: FACS ; IF ; WB
  • Description: Monoclonal antibody directed against DNGR-1 marker for CD8+ dendritic cells, which can be exploited for tumour therapy, whilst also recognising necrotic cells.
  • Immunogen: RBL-2H3 cells expressing mouse DNGR-1 fused to an HA epitope
  • Immunogen uniprot id: Q8BRU4
  • Isotype: IgG1
  • Myeloma used: Y3.AG.1.2.3
  • Recommended controls: Mouse IgG1 isotype-matched control mAbs

Target Details

  • Target: Mouse DNGR1
  • Tissue cell line specificity: Mouse IgG1 isotype-matched control mAbs
  • Target background: This antibody recognises mouse DNGR-1, also known as CLEC9A, which is a highly specific marker of the CD8a+ and the CD103+ DC subsets, as well as a receptor able to recognise a preformed signal exposed on necrotic cells. DNGR-1 was found to be expressed in mice at high levels by CD8+ DCs and at low levels by plasmacytoid DCs, but not by other hematopoietic cells. DNGR-1 is a novel, highly specific marker of mouse and human DC subsets that can be exploited for CTL cross-priming and tumour therapy. DNGR-1 ligation is required for effective cross-presentation of dead-cell-associated antigen by recruitment and activation of the tyrosine kinase Syk. DNGR-1 recognizes filamentous actin in association with particular actin-binding domains of cytoskeletal proteins, including spectrin, exposed when cell membranes are damaged. This antibody can recognise both the short and long isoform of DNGR-1, which vary in a segment of the stalk region.

Applications

  • Application: FACS ; IF ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Shipping at 4° C

References

  • Sancho et al. 2008. J Clin Invest. 118(6):2098-110. PMID: 18497879.